HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

M Lechner, J Liu, L Masterson, TR Fenton - Nature reviews Clinical …, 2022 - nature.com
Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …

Head and neck squamous cell carcinoma

DE Johnson, B Burtness, CR Leemans… - Nature reviews Disease …, 2020 - nature.com
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …

NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines

JJ Caudell, ML Gillison, E Maghami, S Spencer… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity
(including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer …

[HTML][HTML] Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an …

RL Ferris, Y Flamand, GS Weinstein, S Li… - Journal of clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Definitive or postoperative chemoradiation (CRT) is curative for human
papillomavirus–associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity …

Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology

DG Pfister, S Spencer, D Adelstein, D Adkins… - Journal of the National …, 2020 - jnccn.org
Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment …

[HTML][HTML] Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)

SS Yom, P Torres-Saavedra, JJ Caudell… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Reducing radiation treatment dose could improve the quality of life (QOL) of
patients with good-risk human papillomavirus–associated oropharyngeal squamous cell …

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and …

JP Machiels, CR Leemans, W Golusinski… - Annals of …, 2020 - annalsofoncology.org
Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and
occurs in the oral cavity, pharynx and larynx. Nasopharyngeal carcinoma (NPC) is a disease …

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

B Lacas, A Carmel, C Landais, SJ Wong… - Radiotherapy and …, 2021 - Elsevier
Abstract Background and purpose The Meta-Analysis of Chemotherapy in squamous cell
Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) …

The changing therapeutic landscape of head and neck cancer

JD Cramer, B Burtness, QT Le, RL Ferris - Nature reviews Clinical …, 2019 - nature.com
Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …

Clinical update on head and neck cancer: molecular biology and ongoing challenges

E Alsahafi, K Begg, I Amelio, N Raulf, P Lucarelli… - Cell death & …, 2019 - nature.com
Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically
complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies …